Opinion|Videos|September 30, 2024
Safety and Efficacy of HER2-Directed ADCs for NSCLC
Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors guide the choice between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine?
- What key insights emerged from pivotal trials like the phase 2 basket DESTINY-Lung01and DESTINY-Lung02?
- How do real-world patient outcomes compare with those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
5